NCT04486963View on ClinicalTrials.gov

A Phase Ⅱ Clinical Study of Sanhuangjingshimingwan in Wet( Neovascular)Age-related Macular Degeneration(wAMD) Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

July 24, 2020

Primary Completion Date

November 1, 2022

Study Completion Date

November 15, 2022

Conditions
Age-related Macular Degeneration
Interventions
DRUG

Sanhuangjingshimingwan

Sanhuangjingshimingwan,12g,Bid,6 months.Anti VEGF injection will be injected monthly if needed.

DRUG

Sanhuangjingshimingwan Placebo

Sanhuangjingshimingwan Placebo,12g,Bid,6 months.Anti VEGF injection will be injected monthly if needed.

Trial Locations (6)

Unknown

Beijing Hospital, Beijing

Beijing Tongren Hospital, Beijing

The Second Hospital of Hebei Medical University, Shijiazhuang

Shanghai General Hospital, Shanghai

Tianjin Eye Hospital, Tianjin

Tianjin Medical University Eye Hospital, Tianjin

All Listed Sponsors
lead

Tasly Pharmaceutical Group Co., Ltd

INDUSTRY

NCT04486963 - A Phase Ⅱ Clinical Study of Sanhuangjingshimingwan in Wet( Neovascular)Age-related Macular Degeneration(wAMD) Subjects | Biotech Hunter | Biotech Hunter